Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Global vaccine sales "grew by a healthy 16 percent last year, when sales shot up to $22.1 billion, healthcare market research publisher Kalorama Information reported Friday," according to the Associated Press. Kalorama is also forecasting sales "will rise at a compound annual rate of 9.7 percent during the next five years," (Johnson, 8/14).
NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.
BioCryst Pharmaceuticals, Inc. announced that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA for intravenous peramivir to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza. Green Cross Corp. intends to launch peramivir under the commercial name PeramiFlu in South Korea.
Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and six-month periods ended June 30, 2010.
Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010.Total revenue was $1.1 million and $2.5 million for the three and six months ended June 30, 2010, compared to $2.5 million and $2.9 million for the three and six months ended June 30, 2009, respectively.
The Canadian Medical Association (CMA), the College of Family Physicians of Canada (CFPC), and the National Specialty Society of Community Medicine (NSSCM) today released Lessons from the Frontlines, a collaborative report on H1N1 describing the physician experience on the frontlines of the pandemic.
Novavax, Inc. reported today that results from a pre-clinical toxicology study of its vaccine candidate to prevent respiratory syncytial virus, showed the vaccine to be safe and well-tolerated at all doses tested. Novavax's vaccine uses highly purified recombinant particles of RSV-F fusion protein normally found in the virus. There is currently no approved vaccine to prevent RSV infection.
Five of the 15 experts advising the WHO on H1N1 (swine flu) had ties to the pharmaceutical industry, "including for flu vaccine research," according to the Emergency Committee members' list released by the agency Wednesday, Agence France-Presse reports.
Following the WHO's decision on Tuesday to declare the H1N1 (swine flu) pandemic over, several news outlets reviewed the emergence of the virus around the world, exploring how some of the lessons learned from H1N1 could assist the WHO's handling of future outbreaks.
The world is no longer in phase 6 of influenza pandemic alert. We are now moving into the post-pandemic period. The new H1N1 virus has largely run its course.These are the views of members of the Emergency Committee, which was convened earlier today by teleconference.The Committee based its assessment on the global situation, as well as reports from several countries that are now experiencing influenza. I fully agree with the Committee's advice.
Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has been awarded a $21 Million grant from the Defense Advanced Research Projects Agency, Broad Agency Announcement, Defense Sciences Research & Technology to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in the U.S.A. under a Technology Investment Agreement.
"World Health Organisation Director-General Margaret Chan announced Tuesday the end of the [H1N1] swine flu pandemic, more than a year after it was declared," Agence France-Presse reports. "The world is no longer in phase 6 of influenza pandemic alert. We are now moving into the post-pandemic period," Chan said during a virtual press conference from Hong Kong, according to a WHO press release (8/10).
Sharps Compliance Corp., a leading full-service provider of cost-effective management solutions for medical waste and unused dispensed medications generated outside the hospital and large healthcare facility setting, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.
The WHO's decision to declare the H1N1 (swine flu) pandemic officially over could come within weeks, according to WHO Director-General Margaret Chan, the Canadian Press reports.
Novavax, Inc. today announced financial results for the second quarter ended June 30, 2010.
Equatorial Guinea (Republica de Guinea Ecuatorial) and the Global Viral Forecasting Initiative, along with several Central African States, have partnered with the Economic Community of Central African States to form a network to fight H1N1 and HIV. The purpose of the network's recent forum was to share knowledge and best practices, and to collect data and prevention procedures among military health professionals in the region.
BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.
CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.
Emergency Medical Services Corporation today announces results for the second quarter ended June 30, 2010.
STERIS Corporation today announced financial results for its fiscal 2011 first quarter ended June 30, 2010. During the first quarter, the Company recorded the previously announced liability related to the SYSTEM 1 Rebate Program. Of the $110 million pre-tax amount recorded, $102 million is attributable to the Customer Rebate portion of the Program and was recorded as a reduction of revenues, and $8 million is attributable to the disposal of the SYSTEM 1 units to be returned and was recorded as an increase in cost of revenues.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.